Oral Semaglutide
OASIS 4
Novo Nordisk · Phase 3 · Completed · Enrollment 307
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Oral semaglutide 25 mg | n/r | n/r | n/r | n/r |
| Oral semaglutide placebo | n/r | n/r | n/r | n/r |
Not shown
- Oral semaglutide 25 mg: endpoint not reported
- Oral semaglutide placebo: endpoint not reported